^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 underexpression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
2d
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer. (PubMed, JAMA Netw Open)
Additionally, patients with ERBB2-low and low TILs tumors had better BCSM (subdistribution HR, 0.36; 95% CI, 0.14-0.92; P = .03). These findings suggest that there were clinical, pathological, and epidemiological differences between ERBB2-low and ERBB2-negative BC, raising the possibility that ERBB2-low might be a unique biologic entity.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR negative
3d
The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. (PubMed, Breast Cancer Res Treat)
The prognostic value of HER2-low status remains controversial. Our study showed no significant effect of HER2 low expression on survival in patients receiving CDK 4/6i plus ET.
Retrospective data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PTEN mutation + HR positive
|
Ibrance (palbociclib) • Kisqali (ribociclib)
7d
KEYNOTE-797: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=115, Recruiting, Daiichi Sankyo | Trial completion date: Mar 2024 --> Aug 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
8d
Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma. (PubMed, Cancer Med)
A total of 25 common and stable differential metabolites may hold promise as liquid non-invasive indicators for GCA diagnosis. HER2 may function as a tumor suppressor gene in GCA, as its overexpression is associated with improved survival. The downregulation of bile acid metabolism in GCA may offer valuable theoretical insights and innovative approaches for precision-targeted treatments in GCA patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 underexpression
15d
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study. (PubMed, Thorac Cancer)
This study suggested that HER2-low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR-positive/HER2-negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR-positive MBC.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR positive + HER-2 negative • PTEN mutation + HR positive
17d
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
BL-M07D1
25d
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. (PubMed, Breast Cancer)
The strengths of evidence and recommendation were determined through a quantitative and qualitative systematic review using multiple outcomes, including efficacy and safety. We conclude that trastuzumab deruxtecan is recommended for this patient population (strength of recommendation: 1; strength of evidence: moderate; CQ34) and that HER2-low expression for the indication of trastuzumab deruxtecan should be diagnosed using companion diagnostics based on appropriate criteria (FRQ7).
Clinical guideline • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
1m
Trial initiation date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 expression • HER-2 underexpression • PGR expression
|
Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
1m
Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast (USCAP 2024)
HER2 cytoplasmic granular staining was present in 29.7% of pure ACs using PATHWAY 4B5 platform. The rate of HER2 cytoplasmic granular staining on HercepTest platform was significantly lower than that of PATHWAY 4B5 and was only appeared in 2+ and 3+ cases, suggesting that the HercepTest platform is more suitable for the HER2 low expression cases. The IHC interpretation of HER2 3+ were highly consistent with FISH status.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
HercepTest • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
1m
Correlation Study of Four HER2 Immunohistochemical Staining Assays in Breast Cancer and Changes of Heterogeneity Patterns (USCAP 2024)
There was a high level of consensus among the four assays. The changes in HER2 scores among different assays can also cause the changes in heterogeneity patterns.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
1m
Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. (PubMed, Eur Radiol)
• Detecting HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing status in breast cancer patients is crucial for determining candidates for anti-HER2 therapy. • Radiomics features from multiparametric MRI significantly differed among HER2-overexpressing, HER2-low expressing, and HER2-zero-expressing breast cancers. • Multiparametric MRI-based radiomics could preoperatively evaluate three different HER2-expressing statuses and help to determine potential candidates for anti-HER2 therapy in breast cancer patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 underexpression
1m
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors (clinicaltrials.gov)
P1/2, N=42, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Nov 2025 --> Mar 2026 | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
BL-M07D1
1m
Phase classification • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 expression • HER-2 underexpression • PGR positive • PGR negative
|
Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole
2ms
HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy. (PubMed, Cancers (Basel))
However, about 13% of HER2-low MBCs had germline PVs in BRCA1/2 genes, mainly BRCA2, a clinically relevant observation in the context of combined target therapy. Overall, our data, which focused on the largest gender-specific breast cancer series, to our knowledge, confirm that the emerging three-tiered categorization of HER2 (HER2-0, HER2-low, and HER2-positive) can also be considered in MBC, to mitigate both the gender gap and the underrepresentation of males in clinical trials.
Clinical • Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR positive + HER-2 negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
2ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive
|
capecitabine • albumin-bound paclitaxel • BNT323
2ms
A gene expression-based classifier for HER2-low breast cancer. (PubMed, Sci Rep)
These results represent a proof-of-concept for an observer-independent gene-expression-based classifier of HER2-low status. The herein identified 20-gene signature shows promise in distinguishing between HER2 0 and HER2-low expressing tumors, including those scored as 1+ at IHC, and in developing a selection approach for ADCs candidates.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
2ms
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
2ms
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
2ms
Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer. (PubMed, AJR Am J Roentgenol)
CLINICAL IMPACT. MRI radiomics may help select patients for novel or traditional HER2-targeted therapies, particularly in those with ambiguous immunohistochemical results or limited access to fluorescence in situ hybridization.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
2ms
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 (clinicaltrials.gov)
P3, N=366, Recruiting, RemeGen Co., Ltd. | Trial primary completion date: Dec 2023 --> Jun 2024
Trial primary completion date • Metastases
|
HR positive • HER-2 expression • HER-2 underexpression
|
paclitaxel • docetaxel • capecitabine • Aidixi (disitamab vedotin) • vinorelbine tartrate
2ms
DS8201-A-J101: Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov)
P1, N=292, Completed, Daiichi Sankyo Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Dec 2023
Trial completion • Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
3ms
KEYNOTE KN-797: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=115, Recruiting, Daiichi Sankyo, Inc. | Phase classification: P1b --> P1 | Trial primary completion date: Dec 2023 --> Feb 2024
Phase classification • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
3ms
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis. (PubMed, Breast)
Patients diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression of HER2 is supposed to be linked to the prolonged survival of BCBM patients.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
3ms
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy. (PubMed, Breast)
HR positive and HR negative HER2-low breast cancer exhibit different clinicopathological features, response to NAC and HER2 evolution after treatment.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
3ms
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 (clinicaltrials.gov)
P3, N=366, Recruiting, RemeGen Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
HR positive • HER-2 expression • HER-2 underexpression
|
paclitaxel • docetaxel • capecitabine • Aidixi (disitamab vedotin) • vinorelbine tartrate
3ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
trastuzumab rezetecan (SHR-A1811)
4ms
HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes. (PubMed, Sci Rep)
This study identified three HER2 low expression BRCA clusters with different characteristics based on histone modification genes. The TMB, immune cell infiltration, immune checkpoints and drug sensitivity were different among the three clusters.
Journal • Tumor mutational burden • BRCA Biomarker • Epigenetic controller
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • RAD51 (RAD51 Homolog A)
|
HER-2 expression • HER-2 underexpression
4ms
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). (ASCO-GI 2024)
T-DXd monotherapy showed modest single agent activity for locally advanced HER2-positive gastric or GEJ adenocarcinoma in this phase 2 study. An additional cohort combining perioperative T-DXd with capecitabine and durvalumab is planned, to assess whether treatment efficacy and outcomes can be enhanced. Clinical trial information: NCT05034887.
Clinical • P2 data • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
4ms
DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov)
P=N/A, N=1350, Recruiting, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
4ms
Prospective, Single-Arm Phase II Study of Disitamab Vedotin (RC48-ADC) for Early High-Risk or Locally Advanced Estrogen Receptor-Positive/HER2-Low Breast Cancer Treatment (ChiCTR2300072450)
P2, N=56, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 expression • HER-2 underexpression
|
Aidixi (disitamab vedotin)
4ms
IMPACT OF HER2-LOW STATUS IN METASTATIC GASTRIC CANCER (IGICC 2023)
In HER2-low group, 31 patients received mDCF, 16 patients received FOLFOX, 22 patients received capecitabine-cisplatin and 2 patients received other chemotherapy regimens... Among 226 patients, 71 (31.4%) had HER2-low expression and 155 (68.6%) had HER2-zero expression. Patients characteristicas are seen on Table-1. Twelve of the 18 Grade 1 tumours (66%), 41 (40%) of 103 grade 2 tumours and 16 (18%) of 89 grade 3 tumours were HER2-low.
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression • HER-2 underexpression
|
cisplatin • 5-fluorouracil • capecitabine • leucovorin calcium
4ms
Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis. (PubMed, Clin Med Insights Oncol)
Meanwhile, multivariate analysis revealed that HER2-low expression could indicate better OS (P = .047, hazard ratios [HRs] = 16.121, 95% confidence interval [CI] = 1.035-251.046), but it had no prognostic value for DFS or DDFS. When compared with HER2-zero expression, HER2-low expression was not connected to pCR and could not modify metastasis risk in female patients with early-stage breast cancer (BC), but it may prolong patient survival.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
4ms
Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor. (PubMed, Int J Mol Sci)
The bsSORT1×HER2 was further conjugated with DXd to generate a bsADC (bsSORT1×HER2-DXd) that showed strong cytotoxicity on HER2-low-expression tumor cells and antitumor efficacy in an MDA-MB-231 xenograft mice model. These results demonstrated that employment of a SORT1×HER2-targeted bsADC may be promising to improve the antitumor efficacy of HER2-targeted ADC for the treatment of tumors with low HER2 expression.
Journal
|
SORT1 (Sortilin 1)
|
HER-2 expression • HER-2 underexpression
4ms
Prevalence and clinical features of HER2-low breast cancer among Ukrainian population (ABC 2023)
According to the IHC/FISH parameters, the BC with low expression of HER2 is a heterogeneous group of tumors. The amount of HER2-low BC was higher in hormone positive patients (73%) compared to triple-negative (27%). The BC recurrence rate was higher in patients with greater HER2 expression, but it was not statistically significant, p > 0.05.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
4ms
REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2- BREAST CANCER TREATED WITH PALBOCICLIB (ABC 2023)
The majority received Palb as 1L (76%) and letrozole as ET (76%). In our analysis, HER2-low had no impact in PFS. OS was not achieved in the subgroup HER2-low. This study has 3 main limitations: small sample size, retrospective analysis and short follow-up period.
Clinical • Real-world evidence • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Ibrance (palbociclib) • letrozole
4ms
HER2+ ADVANCED BREAST CANCER: NEW DATA, NEW OPPORTUNITIES (ABC 2023)
Without any doubt, the best data come from trastuzumab deruxtecan (TDXd), a third-generation antibody-drug conjugate that had shown in 2021 an impressive improvement in progression-free survival (PFS) compared with TDM1...However, because these studies were not randomized, whether TDXd is a better option compared to tucatinib-based treatment in this setting remains a matter of debate...In the PHOEBE study, pyrotinib and capecitabine were compared with the combination of lapatinib and capecitabine...In addition, the Phila study showed an impressive improvement in PFS when pyrotinib was added to the docetaxel and trastuzumab combination, compared with placebo, trastuzumab and docetaxel. However, since the control arm did not include pertuzumab, this strategy is unlikely to change the standard of care in many countries...However, based on the latest results achieved by TDXd in patients with these cancers, HER2-low expressing tumours have become a new standard terminology. TDXd has shown to improve PFS and OS in patients with HER2-low mBC in the second/ third line treatment compared to the best chemotherapeutic agents (DB04 trial).
Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
|
HER-2 amplification • HER-2 negative • HER-2 underexpression
|
docetaxel • lapatinib • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Irene (pyrotinib) • Tukysa (tucatinib)
4ms
The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. (PubMed, Cancers (Basel))
This extensive single-center study elucidates the favorable prognosis associated with HER2-low status in HR-positive breast cancer. However, this effect differs among premenopausal and postmenopausal patients, necessitating further research into the underlying tumor biology.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PTEN mutation + HR positive
5ms
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
HF158K1
5ms
Clinical and Epidemiologic Significance of HER2-Low Expression in Breast Cancer in the Pathways Study (SABCS 2023)
Background: A subset of breast cancers (BC) typically classified as HER2-negative do express low levels of the protein and can be responsive to targeted therapy trastuzumab-deruxtecan... In this large prospective study with well annotated epidemiologic, clinical, and outcome data, we observed some clinical and epidemiologic differences between HER2-low and HER2-negative patients, raising the possibility that HER2-low might be a unique biologic entity.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • ER positive + PGR positive • PGR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5ms
Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy (SABCS 2023)
Our results show similar pCR rates and RFS among HER2-low and HER2-zero early BC patients after standard NACT, which are consistent with the current literature. Despite the predictive role of low HER2 expression in selecting patients for novel antibody-drug conjugates (ADCs) therapy, its prognostic value could not be confirmed.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 expression • HER-2 underexpression • ER negative
5ms
Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer (SABCS 2023)
Our results showed that HER2-low BC patients had a statistically significant lower frequency of axillary downstaging after NACT. More than 40% of patients with cN+ at diagnosis were downstaged to cN0 and were submitted to SNL biopsy. Axillary dissection were avoided in roughly 25% of patients with cN+ BC at initial staging.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression • HER-2 underexpression
5ms
Can intratumoral microRNA-125a levels be a prognostic biomarker of a ER-positive breast cancer patients? (SABCS 2023)
High miR-125a levels in tumors were associated with aggressive biology and worse survival, thus it can be a candidate for a prognostic biomarker in ER+/HER2- patients.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MKI67 (Marker of proliferation Ki-67) • MIR125A (MicroRNA 125a)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 expression • HER-2 underexpression • ER positive + HER-2 negative